A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT07112872 on ClinicalTrials.gov · last registry update 2026-07-07
An unusually large phase 2: 240 participants, more than double the 114 typical for the stage. Due to report 27 November 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry
- Enrollment
- 240
- Started
- 2025-08-19
- Primary completion
- 2026-11-27 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.